APPROACH
Cancer treatment is full of uncertainty
Physicians haven’t had tools to predict a patient’s response to therapy, leaving both in the dark during major decisions. Valar Labs delivers patient-specific evidence that helps physicians and families make more informed decisions about therapy selection.
APPROACH
Our diagnostics use reliable AI to interpret the tumor microenvironment
Analyzing solid tumors with AI
Our diagnostics interpret digitized pathology slides, using AI algorithms to assess previously unseen spatial features.
Reliable AI physicians can trust
We design transparent AI systems based on underlying biology, so physicians can trust the results. Traditional black box AI diagnostics don’t show you how they work.
Clear, actionable results
Insightful reports show the presence or absence of histology-based biomarkers linked to treatment response, and stratify risk of progression and recurrence.
PATIENTS & FAMILIES
Patients have more confidence and peace of mind
Choosing the best treatment path should be more straightforward. Our diagnostics give timely guidance to patients and families facing cancer, empowering them to make more informed, evidence-based decisions that maximize the likelihood of remission.
ONCOLOGISTS & PHYSICIANS
Physicians are empowered to make informed treatment decisions
Our diagnostics exist so oncologists don’t have to agonize over educated guesses about therapy selection. Rather than relying on odds and averages, our tests enable physicians to interpret unique data from a patient’s tumor and make the best decision informed by all available evidence.
WORKFLOW INTEGRATION
Quick, simple diagnostics fit seamlessly into existing workflows
Seamless integration
Because they use pathology slides, our diagnostics integrate seamlessly into existing molecular testing workflows without adding steps, time, or cost.
Rapid turnaround
Every hour is crucial. Our diagnostics meet the urgency of the moment, delivering actionable results in just hours or days – not weeks or months.
Any cancer center
Our robust algorithms can work with any patient at any hospital on any continent. Tests are based on tumor biology, and aren’t affected by diverse clinical settings.